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Snakebite – A Neglected Tropical Disease
More than 5.5 million people are bitten by venomous snakes per year on a global basis. This 
leads to approx. 125,000 deaths and 3 times as many amputations [1]. Particularly Sub-
Saharan Africa is affected by the problem [2], [3]. Current antivenoms are still being produced by 
a method developed in the 1890’s, in which large mammals (typically horses) are immunized 
with snake venom and antiserum is derived from the animals blood. The incompatibility with the 
human immune system of these animal derived antivenoms leads to a range of side effects, 
such as serum sickness, anaphylaxis, and sometimes even death [2]. Despite the maturity of 
medicinal chemistry and advances in drug development, there remains a need for modern 
antivenoms with better safety profile and improved efficacy [4].
 We have set out to tackle this challenge by attempting to develop the World’s first 
antivenom based on recombinant, humanized antibodies. Such an antivenom will be cheaper to 
produce in large scale and is anticipated to have a much improved safety and efficacy profile.
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Figure 3: ELISA experiment. A purified polyclonal 
mixture of IgG antibodies from a human donor 
that had injected himself with venom from Naja 
kaouthia (Thai cobra), were tested against α-
cobratoxin (α-Cbtx) from Naja kaouthia, 
Dendrotoxin I (Dtx I) from Dendroaspis polylepis 
(Black Mamba), and a control (PBS). A strong 
IgG response is found for the IgGs against α-
Cbtx, but not Dtx I, indicating that the 
administration of Naja kaouthia venom has 
induced an immune response against the 
neurotoxic α-Cbtx, but not Dtx I. The donor had 
never administered venom from Dendroaspis 
polylepis, and the lack of IgG response against 
Dtx I was therefore to be expected.
Methods – Human IgGs Isolated from Human Serum
Serum was obtained from a human donor who had repeatedly injected himself with small 
amounts of snake venom from a range of different snakes, among others Naja kaouthia (Thai 
cobra). From the donor serum, polyclonal IgG antibodies were isolated and purified by 
employing a Protein A Antibody Purification Kit. To assess the presence of IgG antibodies 
directed against cobra venom toxins, an ELISA assay was performed. Detailed experimental 
procedures are is described elsewhere [5].
A bioinformatics analysis was performed, which included visual comparison of the two 
snake toxins α-cobratoxin (PDB entry: 4AEA) and dendrotoxin I (PDB entry: 1DEM) and 
sequence alignment using the protein ClustalW2 algorithm from EMBL-EBI.
Results – α-Cobratoxin and Dendrotoxin I Dissimilar
In the bioinformatics analysis it was shown that the similarity between α-cobratoxin and 
dendrotoxin I was a low 29.63% (see figure 2). This result was unsurprising given that the two 
neurotoxins have different targets (Nicotinic Acetylcholine Receptor [6], and K+ channel [7]).
In the ELISA assay it was shown that the isolated and purified human IgG antibodies had 
a strong response to α-cobratoxin, but not to dendrotoxin I (see figure 3).
Discussion – Cross-reactivity not easily Attainable
Human IgG antibodies induced by immunological challenge with venom from Naja kaouthia 
show reactivity against α-cobratoxin from the same snake species, but not against Dendrotoxin 
I from Dendroaspis polylepis. This is unsurprising, since α-cobratoxin and dendrotoxin I were 
found to be significantly different both in terms of sequence similarity and tertiary structure.
 IgG cross-reactivity against toxins from different snake species cannot generally be 
obtained. Antivenom is most likely to have efficacy in a given snakebite case if the antivenom is 
derived from a mammal that has been immunized with venom from the same (or perhaps in 
some cases: closely related) snake as the snakebite victim has been bitten by.
Future Perspectives – Using FACS for IgG Discovery
Our goal now is to isolate the single-most potent IgG antibody against α-cobratoxin from the 
polyclonal IgG pool and test it as an antitoxin candidate. Two strategies will be pursued (the 
second as a backup) in order to obtain the genetic sequence for the IgG antibody:

•  Isolation of the relevant B-lymphocyte expressing the potent IgG antibody through 
Fluorescence Activated Cell Sorting (FACS) using fluorophore-conjugated α-cobratoxin 
folllowedby amplification of the correct genes and DNA sequencing.
•  Immunoprecipitation of the IgG antibody using beads conjugated with α-cobratoxin followed 
by de novo sequencing by mass spectrometry.
This may pave the way for the World’s first biopharmaceutical antivenom.
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Figure 1: Overview of the current production process for antivenoms and our proposed solution 
employing recombinantly expressed humanized antibodies.
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Figure 2: Cartoon models and surface models drawn in PyMOL of α-cobratoxin (α-Cbtx, PDB 
entry: 4AEA) and dendrotoxin I (Dtx I, PDB entry: 1DEM) and sequence alignment performed 
using the protein ClustalW2 algorithm from EMBL-EBI. Low sequence similarity of 29.63% is 
observed and the secondary and tertiary structures are quite dissimilar.


Naja kaouthia, by Subhro Ganguly [8]
“We will bring antivenom into the 
modern era of biopharmaceuticals”
- Andreas H. Laustsen
